Drug Trial Radar · NCT05361707
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 28, 2021
Primary completion
Jul 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
Conditions
- Autism Spectrum Disorder
- Sleep Disorder
- Neurological Disorder
- Sleep Disturbance
Interventions
Tasimelteon Oral Capsule, Tasimelteon Liquid SuspensionDrug
Once Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in sleep time over the treatment period, as measured by sleep diary.Time frame: 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
San Jose, California · Recruiting
Vanda Investigational Site
San Leandro, California · Recruiting
Vanda Investigational Site
Santa Monica, California · Recruiting
Vanda Investigational Site
Boulder, Colorado · Recruiting
Vanda Investigational Site
Staten Island, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.